SVT 3A4710
Alternative Names: SVT-3A4710Latest Information Update: 28 Mar 2025
At a glance
- Originator Servatus Biopharmaceuticals
- Class Anti-inflammatories; Bacteria; Skin disorder therapies
- Mechanism of Action Bacteria replacements; Gastrointestinal microbiome modulators; Microbiome modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Atopic dermatitis; Inflammatory bowel diseases; Skin disorders
Most Recent Events
- 28 Mar 2025 No recent reports of development identified for preclinical development in Atopic-dermatitis in Australia
- 28 Mar 2025 No recent reports of development identified for preclinical development in Inflammatory-bowel-diseases in Australia
- 28 Mar 2025 No recent reports of development identified for preclinical development in Skin-disorders in Australia